GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiora Pharmaceuticals Inc (FRA:7EY) » Definitions » Interest Received

Kiora Pharmaceuticals (FRA:7EY) Interest Received


View and export this data going back to 2017. Start your Free Trial

What is Kiora Pharmaceuticals Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.


Kiora Pharmaceuticals Business Description

Traded in Other Exchanges
Address
332 Encinitas Boulevard, Suite 102, Encinitas, CA, USA, 92024
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.